This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
More data to expand its indication from chronic kidney disease to all adult iron defi ciency anemia in patients who have failed or cannot tolerate oral iron treatment Norethindrone (Actavis) Contraceptive patch applied once weekly; concern regarding the difference in size and formulation of the patch used in the clinical trials and the to-bemarketed patch
Delayed decision by the FDA

Vedolizumab (Takeda Pharmaceutical)
Prescription Drug User Fee Act Priority Review action date for the ulcerative colitis indications has been moved to May 20, 2014 to allow the FDA to review newly submitted information. Warning Hepatotoxicity • Clinically signifi cant liver injury, including acute liver failure requiring transplant, has been reported in patients treated with natalizumab in the postmarketing setting. Signs of liver injury, including markedly elevated serum hepatic enzymes and elevated total bilirubin, occurred as early as 6 days after the fi rst dose; signs of liver injury have also been reported for the fi rst time after multiple doses. In some patients, liver injury recurred upon rechallenge, providing evidence that natalizumab caused the injury. The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury that may lead to death or the need for a liver transplant in some patients. Natalizumab should be discontinued in patients with jaundice or other evidence of signifi cant liver injury (eg, laboratory evidence Using more than one dose in 24 hours of over-the-counter (OTC) sodium phosphate drugs to treat constipation can cause rare but serious harm to the kidneys and heart and even death. Reports included episodes of severe dehydration and changes in the levels of serum electrolytes, resulting in serious adverse effects on organs, such as the kidneys and heart, and in some cases resulting in death. Individuals that may be at higher risk for potential adverse events include young children; individuals older than 55 years; patients who are dehydrated; patients with kidney disease, bowel obstruction, or infl ammation of the bowel; and patients who are using medications that may affect kidney function (eg, diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and nonsteroidal antiinfl ammatory drugs). Caregivers should not give the oral products to children 5 years and younger without fi rst discussing with a health care professional. Health care professionals should use caution when recommending an oral dose of these products for children 5 years and younger. The rectal form of these products should never be given to children younger than 2 years. http://www.fda.gov/Drugs/DrugSafety/ucm380757.htm
